Ownership and insider activity for aTyr Pharma, Inc. (ATYR): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2.
Price
| Price | $0.38 |
| Market Cap | $38M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-05-27 | SCHIMMEL PAUL | P-Purchase | 100,000 | $50K |
| 2026-05-11 | Coughlin Timothy | A-Award | 50,000 | $48K |
| 2026-05-11 | BENEVICH ERIC | A-Award | 50,000 | $48K |
| 2026-05-11 | Gross Jane A | A-Award | 50,000 | $48K |
| 2026-05-11 | Lucas Svetlana | A-Award | 50,000 | $48K |
| 2026-05-11 | Zaknoen Sara | A-Award | 50,000 | $48K |
| 2026-05-11 | SCHIMMEL PAUL | A-Award | 50,000 | $48K |
| 2026-02-03 | Shukla Sanjay | M-Exempt | 10,375 | |
| 2026-02-04 | Shukla Sanjay | S-Sale | 3,745 | $4K |
| 2026-02-03 | Shukla Sanjay | M-Exempt | 10,375 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $38.4M | $21.1M | $23.0M | $9.2M | $17.0M | $2.3M | $10.0M | $22.5M | $11.1M | $10.7M |
| Short-term Investments | $33.8M | $64.0M | $26.6M | $21.9M | $14.7M | $105.6M | $56.2M | $75.6M | $61.1M | $67.9M |
| Receivables | 0 | 0 | 0 | $100000 | $2.0M | $435000 | $11.8M | $2.4M | $1.7M | $873000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $74.8M | $87.0M | $50.8M | $31.9M | $35.5M | $113.6M | $80.9M | $103.0M | $82.0M | $80.2M |
| Property, Plant & Equipment | $1.4M | $2.3M | $1.9M | $4.1M | $3.0M | $1.8M | $11.6M | $14.0M | $11.9M | $10.4M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $80.5M | $89.4M | $52.7M | $36.2M | $38.7M | $115.5M | $95.8M | $120.7M | $96.8M | $94.2M |
| Accounts Payable | $2.6M | $2.3M | $1.0M | $847000 | $1.4M | $1.0M | $3.1M | $3.5M | $4.3M | $3.9M |
| Short-term Debt | $339000 | $5.0M | $7.8M | $8.7M | 0 | 0 | 0 | 0 | 0 | $1.5M |
| Total Current Liabilities | $8.5M | $10.4M | $10.8M | $12.9M | $5.9M | $6.0M | $13.9M | $16.4M | $15.0M | $15.1M |
| Long-term Debt | $9.2M | $14.7M | $8.3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $17.7M | $25.1M | $19.1M | $15.2M | $7.2M | $6.4M | $24.5M | $30.2M | $27.0M | $26.9M |
| Retained Earnings | -$216.0M | -$264.2M | -$298.7M | -$322.3M | -$338.5M | -$372.3M | -$417.6M | -$468.0M | -$532.0M | -$606.2M |
| Total Equity | $62.8M | $64.2M | $33.6M | $21.2M | $31.6M | $109.3M | $71.5M | $90.7M | $70.0M | $67.5M |
| Total Debt | $9.5M | $19.7M | $16.0M | $11.7M | $2.2M | $1.4M | $11.5M | $15.1M | $13.3M | $12.0M |
| Net Debt | -$62.6M | -$65.4M | -$33.5M | -$19.4M | -$29.4M | -$106.5M | -$54.6M | -$83.1M | -$58.8M | -$66.7M |
| Working Capital | $66.2M | $76.6M | $40.0M | $19.0M | $29.7M | $107.6M | $67.0M | $86.6M | $67.0M | $65.1M |
Financial Health
| Debt / Equity | 0.23 |
| Current Ratio | 5.12 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -9.28 |
Profitability
| Return on Equity | -109.84% |
| Return on Invested Capital | -96.45% |
| Return on Assets | -78.71% |
| Gross Margin | -11754.74% |
| Operating Margin | -33609.47% |
| Net Margin | -32003.68% |
Related companies: ACRV · ALXO · CAMP · DTIL · HYFT · MGX · QNCX
Explore sector: Healthcare · Biotechnology
More sections of ATYR: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks